4 news items
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP
3 Jun 24
statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Advancing US FDA Process, Featured Among Top Health Care Movers
ABEO
ADAP
INBS
31 May 24
the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
and unknown risks, uncertainties and other factors which might cause Galapagos' actual results to be materially different from those expressed
- Prev
- 1
- Next